Ildong Pharmaceutical and Japan's Shionogi Pharmaceutical Jointly Develop Oral COVID-19 Treatment

[Asia Economy Reporter Ji-hwan Park] Ildong Pharmaceutical is partnering with a Japanese pharmaceutical company to develop an oral COVID-19 treatment.

On the 17th, Ildong Pharmaceutical announced that it received approval from the Ministry of Food and Drug Safety (MFDS) for the domestic Phase 2/3 clinical trial plan (IND) of the oral COVID-19 treatment candidate substance ‘S-217622’. Following the MFDS approval of the Phase 2 and Phase 3 clinical trial plans for this candidate substance, Ildong Pharmaceutical will commence domestic clinical development.

The domestic clinical trials will be conducted on approximately 200 asymptomatic, mild, and moderate COVID-19 patients. Phase 2a will be followed by Phase 2b and Phase 3 trials.

Ildong Pharmaceutical will conduct the global clinical trials domestically, while Shionogi Pharmaceutical will carry out trials in Japan, Singapore, and other countries.

Ildong Pharmaceutical and Shionogi Pharmaceutical are working towards obtaining emergency use authorization for this product from the Korean MFDS in the first half of next year. After commercialization, domestic production is also planned through technology transfer.

This content was produced with the assistance of AI translation services.